Lena P Thia
Overview
Explore the profile of Lena P Thia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
233
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hoppe J, Kasi A, Pittman J, Jensen R, Thia L, Robinson P, et al.
Lancet Respir Med
. 2025 Jan;
13(3):244-255.
PMID: 39756425
Background: In phase 2 trials in people with cystic fibrosis aged 18 years and older, vanzacaftor-tezacaftor-deutivacaftor has been shown to be a safe and effective, once-daily cystic fibrosis transmembrane conductance...
2.
Doull I, Course C, Hanks R, Southern K, Forton J, Thia L, et al.
Arch Dis Child
. 2020 Aug;
106(3):253-257.
PMID: 32859613
Objective: Wales has an immunoreactive trypsin (IRT)-DNA cystic fibrosis (CF) newborn screening (NBS) programme. Most CF NBS false negative cases are due to an IRT concentration below the screening threshold....
3.
Davies G, Thia L, Stocks J, Bush A, Hoo A, Wade A, et al.
J Cyst Fibros
. 2020 Feb;
19(6):896-901.
PMID: 32044244
Background: With the widespread introduction of newborn screening for cystic fibrosis (CF), there has been considerable emphasis on the need to develop objective markers of lung health that can be...
4.
Forton J, Doull I, Thia L
Lancet Respir Med
. 2018 Jul;
6(10):e52.
PMID: 30037712
No abstract available.
5.
Ronchetti K, Tame J, Paisey C, Thia L, Doull I, Howe R, et al.
Lancet Respir Med
. 2018 May;
6(6):461-471.
PMID: 29778403
Background: Pathogen surveillance is challenging but crucial in children with cystic fibrosis-who are often non-productive of sputum even if actively coughing-because infection and lung disease begin early in life. The...
6.
Davies G, Stocks J, Thia L, Hoo A, Bush A, Aurora P, et al.
Eur Respir J
. 2017 Nov;
50(5).
PMID: 29122914
With the advent of novel designer molecules for cystic fibrosis (CF) treatment, there is huge need for early-life clinical trial outcomes, such as infant lung function (ILF). We investigated the...
7.
Thia L, Calder A, Stocks J, Bush A, Owens C, Wallis C, et al.
Thorax
. 2013 Oct;
69(4):320-7.
PMID: 24132911
Rationale: Sensitive outcome measures applicable in different centres to quantify and track early pulmonary abnormalities in infants with cystic fibrosis (CF) are needed both for clinical care and interventional trials....
8.
Evolution of lung function during the first year of life in newborn screened cystic fibrosis infants
Nguyen T, Thia L, Hoo A, Bush A, Aurora P, Wade A, et al.
Thorax
. 2013 Sep;
69(10):910-7.
PMID: 24072358
Rationale: Newborn screening (NBS) for cystic fibrosis (CF) allows early intervention. Design of randomised controlled trials (RCT) is currently impeded by uncertainty regarding evolution of lung function, an important trial...
9.
Urquhart D, Thia L, Francis J, Prasad S, Dawson C, Wallis C, et al.
Arch Dis Child
. 2012 Dec;
98(2):123-7.
PMID: 23264431
Introduction: Death in childhood from cystic fibrosis (CF) is now an uncommon event in the U.K. We wished to assess the circumstances surrounding deaths (and lung transplantation) in the modern...
10.
Stocks J, Thia L, Sonnappa S
Curr Opin Pulm Med
. 2012 Oct;
18(6):602-8.
PMID: 23026833
Purpose Of Review: Lung disease begins early in life in cystic fibrosis (CF), yet our understanding of CF lung abnormalities in the first years of life remains limited. By facilitating...